Frank van Haren

Heparin Therapeutics is a clinical-stage biotechnology company focused on developing inhaled treatments for severe respiratory diseases. Co-founded by Professor Frank van Haren and Professor Clive Page, the company leverages the multi-modal properties of unfractionated heparin (UFH) to treat lung injury and inflammation. Its lead candidate, HT-231, is a proprietary nebulized formulation of UFH designed for direct delivery to the lungs via a specialized platform. Clinical data from international meta-trials have demonstrated that inhaled UFH can significantly reduce intubation rates and mortality in patients with COVID-19 and Acute Respiratory Distress Syndrome (ARDS). The company is also exploring the application of its technology in other respiratory conditions such as COPD and asthma.